Iran antirheumatic drugs market was valued at US$1,519.779 million in 2019. The market for antirheumatic drugs in Iran is projected to grow account of the high prevalence of rheumatoid arthritis in the country along with the presence of a considerably high proportion of the geriatric population in the country. Furthermore, the rising incidence of cardiovascular diseases in the country is also anticipated to be one of the key factors supplementing the market growth in the country during the next five years. For instance, according to the data from the World Health Organization, the deaths in the country due to cardiovascular diseases increased by 21% from 2007 to 2017. Also, the burden of CVD will increase by more than double the rate in 2005 by the year 2025. Additionally, the high number of cases in the country with active malaria foci is also anticipated to bolster the demand for antirheumatic drugs in the country, thereby positively impacting the market growth during the next five years. For instance, according to the report from the World Health Organization, the number of people living with an active foci were more than 340,000 during the year 2017.
Furthermore, rising participation of domestic pharmaceutical companies in the form of growing investments in pharma R&D for the development of numerous high-cost drugs domestically with an aim to tap the potential of the market that it holds also widens up the opportunities for the market to grow during the next five years. For instance, in February 2019, NanoAlvand Pharmaceuticals, an Iranian pharmaceutical manufacturing company announced the launch of a new drug Rhofanib 5, completely designed and manufactured in Iran for the treatment of rheumatoid arthritis.
Iran antirheumatic drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis,rheumatoid arthritis, gout, lupus, and others. By type of molecule, the Iran antirheumatic drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).